Preclinical advances in antibodies against N‐terminal Aβ4‐x species for Alzheimer's disease and cerebral amyloid angiopathy
Ibrain · 2026-03 · 12 (1) · 52-64
DOI: 10.1002/ibra.70016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ibrain, online erschienen am 01.03.2026. Verfasst von Maria Luisa Valle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology NYU Grossman School of Medicine New York New York USA. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerul Educaţiei Naţionale.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) pathogenesis is characterized by the accumulation of amyloid beta (Aβ) deposits in the cerebral parenchyma and vasculature, a condition referred to as cerebral amyloid angiopathy (CAA). Besides the full‐length form, Aβ deposits showed a highly heterogenous composition due to the action of different proteolytic enzymes. N‐terminal Aβ peptides have shown higher aggregation propensity and toxicity compared to the other truncated forms, with species starting at residue phenylalanine 4 (Aβ4‐x) being more neurotoxic than the others. Thus, Aβ4‐x species have drawn attention in AD pathogenesis, potentially offering novel therapeutic targets to halt or reverse disease progression. Antibodies targeting specifically Aβ4‐x species were designed with the aim of preventing their aggregation and promoting their clearance counterbalancing their neurotoxic effect. This work provides an update on monoclonal and polyclonal antibodies developed to specifically target Aβ4‐x species in AD and CAA preclinical studies (in vitro and in vivo models).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology NYU Grossman School of Medicine New York New York USA.
- Department of Psychiatry San Diego State University San Diego California USA.
ORCID-Profile: Maria Luisa Valle
Förderung
- Ministerul Educaţiei Naţionale
Zitieren
APA
Valle, M. L., & Arienzo, D. (2026). Preclinical advances in antibodies against N‐terminal Aβ4‐x species for Alzheimer's disease and cerebral amyloid angiopathy. Ibrain, 12(1), 52-64. https://doi.org/10.1002/ibra.70016
Vancouver
Valle ML, Arienzo D. Preclinical advances in antibodies against N‐terminal Aβ4‐x species for Alzheimer's disease and cerebral amyloid angiopathy. Ibrain. 2026;12(1):52-64. doi:10.1002/ibra.70016
BibTeX
@article{Valle2026,
author = {Valle, Maria Luisa and Arienzo, Donatello},
title = {Preclinical advances in antibodies against N‐terminal Aβ4‐x species for Alzheimer's disease and cerebral amyloid angiopathy},
journal = {Ibrain},
year = {2026},
volume = {12},
number = {1},
pages = {52--64},
doi = {10.1002/ibra.70016}
}
EUVIMED